Key facts
- AuB’s last known valuation is $19.1M (Jul 2025).
- It has raised $8.0M; the latest was Later Stage VC ($2.0M) in Jul 2025.
- Notable investors include Mitsubishi UFJ Capital, Shizuoka Capital, Taisho Pharmaceutical Holdings, Kyocera, LINK-J — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for AuB
- ·The full record, as it builds
Funding rounds
No funding rounds for AuB are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AuB
Manufacturer of health products intended to provide nutrition and encourage fitness. The company offers supplements based on the research of microbiome and stool samples of athletes and also provides services like dietary improvement services based on the results of an athlete's intestinal flora data, enabling consumers and athletes to improve performance.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2015
- Website
- aub.co.jp/
- Ownership
- Privately Held (backing)
AuB doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AuB shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AuB in its N-PORT filings yet. We sweep new filings monthly.